Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tongli Biomedical Co. Ltd. has 1 pending office action in Biotechnology & Pharmaceuticals. The profile lists 1 distinct examiner and 1 distinct art unit. HORLICK, KENNETH R is the busiest examiner, with 1 pending matter. The supplied figures show a single examination path for the company’s biomedical subject matter.
The response should give priority to the action’s stated grounds and to a clear explanation of the claimed biomedical features. Counsel should connect amendments to the application disclosure and distinguish the cited art using technically specific reasoning. The concentrated assignment structure supports one coherent prosecution position, while the existing file history should remain the main reference for deciding how much claim modification is necessary.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HORLICK, KENNETH R | 1 | 79.0% | +15.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023793 | METHOD FOR PREPARING TEST SOLUTION FOR PATHOGEN DETECTION PURPOSE,SYSTEM, KIT, DETECTION PRIMER AND METHOD THEREBY | HORLICK, KENNETH R | 31d overdue |
| Art Unit | Apps |
|---|---|
| 1681 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18023793 | METHOD FOR PREPARING TEST SOLUTION FOR PATHOGEN DETECTION PURPOSE,SYSTEM, KIT, DETECTION PRIMER AND METHOD THEREBY | HORLICK, KENNETH R | 1681 | §103 | Final Rejection | 31d overdue | Pending | Feb 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTongli Biomedical Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.
Kenneth R Horlick has the most, with 1 of Tongli Biomedical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.